Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2014
Event Date: November 3, 2014
Context: The Company entered into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics
This filing reports on a specific transaction rather than periodic financial performance. Key transaction metrics include:
- Shares Issued: 696,378 shares of common stock.
- Price Per Share: $7.18 (equal to the closing price on October 31, 2014).
- Gross Proceeds: Approximately $5 million.
- Transaction Costs: Finder's fee of up to $155,000.
- Break-up Fees: $1 million payable by either party depending on the cause of failure to close within 30 days of the expected closing date.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the agreement to sell unregistered equity securities to Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. This transaction is expected to increase the Company's cash position by approximately $5 million upon closing, subject to conditions.
Guidance, Outlook, and Risks
- Expected Closing: On or about November 28, 2014.
- Contingencies: Closing is subject to customary conditions in securities purchase agreements. If conditions are not met, the sale may not close.
- Forward-Looking Statements: The Company warns that statements regarding the closing date and intent are not guaranteed and may not occur due to reasons beyond its control.
- Regulatory Status: The sale was made in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act and Regulation D.
Investor Verification Checklist
- Verify the actual closing date of the transaction (expected November 28, 2014).
- Confirm receipt of the full $5 million purchase price by the Company.
- Review the definitive Stock Purchase Agreement (Exhibit 10.1) for specific conditions precedent to closing.
- Monitor for any announcements regarding the payment of the $1 million break-up fee if the transaction fails to close within the specified timeframe.